AUP - Aurinia Pharmaceuticals Stock Price, News & Analysis

C$6.88 0.16 (2.38 %)
(As of 11/24/2017 11:27 AM ET)
Previous CloseC$6.72
Today's RangeC$6.77 - C$7.07
52-Week RangeC$2.75 - C$14.17
Volume47,679 shs
Average Volume122,593 shs
Market CapitalizationC$573.89 million
P/E RatioN/A
Dividend YieldN/A
Beta3.17

About Aurinia Pharmaceuticals (TSE:AUP)

Aurinia Pharmaceuticals logoAurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.


Industry, Sector and Symbol

Industry Technical & System Software
Sub-IndustryN/A
SectorTechnology
SymbolTSE:AUP
  • Previous Symbol: TSE:ISA
  • CUSIPN/A

    Debt

    Debt-to-Equity RatioN/A
    Current RatioN/A
    Quick RatioN/A

    Price-To-Earnings

    Trailing P/E RatioN/A
    Forward P/E RatioN/A
    P/E GrowthN/A

    Sales & Book Value

    Annual SalesN/A
    Price / SalesN/A
    Cash FlowN/A
    Price / CashN/A
    Book ValueN/A
    Price / BookN/A

    Dividend

    Annual DividendN/A
    Dividend YieldN/A

    Profitability

    Trailing EPSC($1.66)
    Net IncomeN/A
    Net Margins-729.18%
    Return on Equity-5.48%
    Return on Assets-4.50%

    Miscellaneous

    EmployeesN/A
    Outstanding Shares83,485,000

    Frequently Asked Questions for Aurinia Pharmaceuticals (TSE:AUP)

    What is Aurinia Pharmaceuticals' stock symbol?

    Aurinia Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AUP."

    When will Aurinia Pharmaceuticals make its next earnings announcement?

    Aurinia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March, 8th 2018. View Earnings Estimates for Aurinia Pharmaceuticals.

    Who are some of Aurinia Pharmaceuticals' key competitors?

    Who are Aurinia Pharmaceuticals' key executives?

    Aurinia Pharmaceuticals' management team includes the folowing people:

    • Richard M. Glickman LL.D., Executive Chairman of the Board, Chief Executive Officer (Age 57)
    • Dennis Bourgeault, Chief Financial Officer, Corporate Secretary
    • Michael R. Martin, Chief Operating Officer
    • Neil Solomons M.D., Chief Marketing Officer
    • Celia Economides, Associate Vice President, Corporate Communications & Patient Advocacy
    • Robert B. Huizinga, Vice President - Clinical Affairs
    • Lawrence D. Mandt, Vice President - Regulatory and Quality (Age 57)
    • George M. Milne Jr., Ph.D., Director (Age 73)
    • Lorin Jeffry Randall, Director (Age 73)
    • Benjamin Rovinski Ph.D., Independent Director (Age 58)

    How do I buy Aurinia Pharmaceuticals stock?

    Shares of Aurinia Pharmaceuticals and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

    What is Aurinia Pharmaceuticals' stock price today?

    One share of Aurinia Pharmaceuticals stock can currently be purchased for approximately C$6.88.

    How big of a company is Aurinia Pharmaceuticals?

    Aurinia Pharmaceuticals has a market capitalization of C$573.89 million.

    How can I contact Aurinia Pharmaceuticals?

    Aurinia Pharmaceuticals' mailing address is 1203-4464 Markham St, VICTORIA, BC V8Z 7X8, Canada. The company can be reached via phone at +1-250-7084272.


    MarketBeat Community Rating for Aurinia Pharmaceuticals (AUP)

    Community Ranking:  2.8 out of 5 (star star)
    Outperform Votes:  43 (Vote Outperform)
    Underperform Votes:  34 (Vote Underperform)
    Total Votes:  77
    MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

    Analyst Ratings

    Analysts' Consensus Rating for Aurinia Pharmaceuticals (TSE:AUP)

      (How are Consensus Ratings Calculated?)
    Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings
    Consensus Rating:Buy (Score: 3.00)
    Analysts' Consensus Price Target: N/A

    Consensus Price Target History for Aurinia Pharmaceuticals (TSE:AUP)

    Price Target History for Aurinia Pharmaceuticals (TSE:AUP)

    Analysts' Ratings History for Aurinia Pharmaceuticals (TSE:AUP)

    Show:
    DateFirmActionRatingPrice TargetDetails
    10/6/2017Seaport Global SecuritiesReiterated RatingBuyView Rating Details
    5/15/2017Leerink SwannReiterated RatingOutperformView Rating Details
    11/4/2016Bloom BurtonReiterated RatingBuyView Rating Details
    11/1/2016MackieReiterated RatingSpeculative BuyView Rating Details
    (Data available from 11/24/2015 forward)

    Earnings

    Earnings History for Aurinia Pharmaceuticals (TSE:AUP)


    No earnings announcements for this company have been tracked by MarketBeat.com

    Estimates

    Earnings Estimates for Aurinia Pharmaceuticals (TSE:AUP)
    QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
    Q2 20171($0.18)($0.18)($0.18)
    Q3 20171($0.19)($0.19)($0.19)
    Q4 20172($0.22)($0.10)($0.16)
    (Data provided by Zacks Investment Research)

    Dividends

    Dividend History for Aurinia Pharmaceuticals (TSE:AUP)
    No dividend announcements for this company have been tracked by MarketBeat.com

    Insider Trades

    Insider Trading and Institutional Ownership History for Aurinia Pharmaceuticals (TSE AUP)

    Insider Trades by Quarter for Aurinia Pharmaceuticals (TSE:AUP)

    Insider Trades by Quarter for Aurinia Pharmaceuticals (TSE AUP)

    Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
    1/12/2017Rashieda GluckInsiderBuy50C$0.10C$5.00
    3/23/2016Rashieda GluckInsiderSell1,500C$3.00C$4,500.00
    (Data available from 1/1/2013 forward)

    Headlines

    Latest Headlines for Aurinia Pharmaceuticals (TSE AUP)

    Source:
    DateHeadline
    Aurinia Pharmaceuticals, Inc. :AUP-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 23, 2017Aurinia Pharmaceuticals, Inc. :AUP-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 23, 2017
    finance.yahoo.com - November 23 at 3:38 PM
    FY2017 EPS Estimates for Aurinia Pharmaceuticals Inc Cut by Cantor Fitzgerald (AUP)FY2017 EPS Estimates for Aurinia Pharmaceuticals Inc Cut by Cantor Fitzgerald (AUP)
    www.americanbankingnews.com - November 22 at 5:54 AM
    Brokers Issue Forecasts for Aurinia Pharmaceuticals Incs Q4 2017 Earnings (AUP)Brokers Issue Forecasts for Aurinia Pharmaceuticals Inc's Q4 2017 Earnings (AUP)
    www.americanbankingnews.com - November 17 at 10:12 PM
    FY2017 Earnings Estimate for Aurinia Pharmaceuticals Inc (AUP) Issued By Leerink SwannFY2017 Earnings Estimate for Aurinia Pharmaceuticals Inc (AUP) Issued By Leerink Swann
    www.americanbankingnews.com - November 17 at 8:08 PM
    14 Stocks Moving In Tuesdays After-Hours Session - Benzinga14 Stocks Moving In Tuesday's After-Hours Session - Benzinga
    www.benzinga.com - November 15 at 2:43 AM
    Aurinia Reports Third Quarter 2017 Financial Results and Provides Operational Highlights - Business Wire (press release)Aurinia Reports Third Quarter 2017 Financial Results and Provides Operational Highlights - Business Wire (press release)
    www.businesswire.com - November 15 at 2:43 AM
    Aurinia Pharmaceuticals Inc (AUP) Set to Announce Quarterly Earnings on TuesdayAurinia Pharmaceuticals Inc (AUP) Set to Announce Quarterly Earnings on Tuesday
    www.americanbankingnews.com - November 8 at 10:14 AM
    Cramers lightning round: Im concerned about GameStop ahead of the holidays - CNBCCramer's lightning round: I'm concerned about GameStop ahead of the holidays - CNBC
    www.cnbc.com - November 4 at 5:46 PM
    Aurinia Pharmaceuticals: R&D Day Update On Its Clinical Program And Pipeline DevelopmentAurinia Pharmaceuticals: R&D Day Update On Its Clinical Program And Pipeline Development
    seekingalpha.com - October 31 at 3:12 AM
    Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AUP-CA : October 23, 2017Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AUP-CA : October 23, 2017
    finance.yahoo.com - October 23 at 3:57 PM
    Aurinia to Expand Renal Franchise with Novel Indications and Launches Development Program for Treatment of Dry ... - Business Wire (press release)Aurinia to Expand Renal Franchise with Novel Indications and Launches Development Program for Treatment of Dry ... - Business Wire (press release)
    www.businesswire.com - October 21 at 8:58 PM
    Why High-Flying Aurinia Pharmaceuticals Stock Could Still Be Dirt Cheap - Motley FoolWhy High-Flying Aurinia Pharmaceuticals Stock Could Still Be Dirt Cheap - Motley Fool
    www.fool.com - October 15 at 2:06 AM
    Should You Buy Aurinia Pharmaceuticals Inc (AUPH)?Should You Buy Aurinia Pharmaceuticals Inc (AUPH)?
    finance.yahoo.com - October 13 at 9:50 PM
    Why High-Flying Aurinia Pharmaceuticals Stock Could Still Be Dirt CheapWhy High-Flying Aurinia Pharmaceuticals Stock Could Still Be Dirt Cheap
    finance.yahoo.com - October 13 at 4:50 PM
    Millennial investor mindful of Indigenous rights and climate change - The Globe and MailMillennial investor mindful of Indigenous rights and climate change - The Globe and Mail
    www.theglobeandmail.com - October 7 at 4:51 PM
    Research Initiated on Healthcare Stocks, Oncolytics Biotech, Aurinia Pharma, Immunovaccine, and IntelliPharmaCeutics InternationalResearch Initiated on Healthcare Stocks, Oncolytics Biotech, Aurinia Pharma, Immunovaccine, and IntelliPharmaCeutics International
    finance.yahoo.com - October 3 at 3:57 PM
    Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AUP-CA : September 29, 2017Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AUP-CA : September 29, 2017
    finance.yahoo.com - October 2 at 4:07 PM
    Aurinia Pharmaceuticals, Inc. – Value Analysis (TORONTO:AUP) : October 2, 2017Aurinia Pharmaceuticals, Inc. – Value Analysis (TORONTO:AUP) : October 2, 2017
    finance.yahoo.com - October 2 at 4:07 PM
    Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AUP-CA : September 13, 2017Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AUP-CA : September 13, 2017
    finance.yahoo.com - September 13 at 5:25 PM
    Aurinia Pharmaceuticals stock has tripled so far in 2017. Heres why that could be just the start. - Motley FoolAurinia Pharmaceuticals stock has tripled so far in 2017. Here's why that could be just the start. - Motley Fool
    www.fool.com - September 2 at 8:54 PM
    Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AUP-CA : September 1, 2017Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AUP-CA : September 1, 2017
    finance.yahoo.com - September 1 at 4:45 PM
    Too Many People Own StocksToo Many People Own Stocks
    finance.yahoo.com - August 31 at 9:10 PM
    Aurinia Pharmaceuticals Inc Expected to Earn FY2017 Earnings of ($1.27) Per Share (AUP)Aurinia Pharmaceuticals Inc Expected to Earn FY2017 Earnings of ($1.27) Per Share (AUP)
    www.americanbankingnews.com - August 28 at 2:28 AM
    3 Reasons to Buy Aurinia Pharmaceuticals Stock Right Now3 Reasons to Buy Aurinia Pharmaceuticals Stock Right Now
    finance.yahoo.com - August 25 at 2:20 AM
    Aurinia Pharmaceuticals, Inc. :AUP-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 15, 2017Aurinia Pharmaceuticals, Inc. :AUP-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 15, 2017
    finance.yahoo.com - August 15 at 5:08 PM
    Aurinia Pharmaceuticals, Inc. :AUP-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 3, 2017Aurinia Pharmaceuticals, Inc. :AUP-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 3, 2017
    finance.yahoo.com - August 3 at 10:36 PM
    Aurinia Pharmaceuticals, Inc. – Value Analysis (TORONTO:AUP) : August 1, 2017Aurinia Pharmaceuticals, Inc. – Value Analysis (TORONTO:AUP) : August 1, 2017
    finance.yahoo.com - August 1 at 11:40 PM
    Aurinia Pharmaceuticals Inc (TSE:AUP) Set to Announce Earnings on ThursdayAurinia Pharmaceuticals Inc (TSE:AUP) Set to Announce Earnings on Thursday
    www.americanbankingnews.com - July 27 at 7:16 AM
    3 Been-There-Done-That Biotech CEOs Who Are Doing it Again - Motley Fool3 Been-There-Done-That Biotech CEOs Who Are Doing it Again - Motley Fool
    www.fool.com - July 21 at 10:42 PM
    Billionaires Bet Big On Canada’s Cannabis FrenzyBillionaires Bet Big On Canada’s Cannabis Frenzy
    www.baystreet.ca - July 21 at 5:42 PM
    Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AUP-CA : July 18, 2017Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AUP-CA : July 18, 2017
    finance.yahoo.com - July 18 at 5:41 PM
    Cramer Remix: Why its still worth owning Procter & Gamble - CNBCCramer Remix: Why it's still worth owning Procter & Gamble - CNBC
    www.cnbc.com - July 18 at 2:33 AM
    Cramer Remix: Why it’s still worth owning Procter & GambleCramer Remix: Why it’s still worth owning Procter & Gamble
    finance.yahoo.com - July 17 at 9:31 PM
    3 Small Biotech Stocks Being Run by Proven Winners - Motley Fool3 Small Biotech Stocks Being Run by Proven Winners - Motley Fool
    www.fool.com - July 17 at 12:31 PM
    Is Aurinia Pharmaceuticals' Management Its Best Asset?Is Aurinia Pharmaceuticals' Management Its Best Asset?
    finance.yahoo.com - July 14 at 11:04 PM
    Aurinia Resolves Temporary Non-Compliance with Nasdaq’s Audit Committee Composition RuleAurinia Resolves Temporary Non-Compliance with Nasdaq’s Audit Committee Composition Rule
    finance.yahoo.com - July 12 at 9:44 PM
    After Its Drop, Is Aurinia Pharmaceuticals Stock Now A Buy?After Its Drop, Is Aurinia Pharmaceuticals Stock Now A Buy?
    finance.yahoo.com - July 12 at 9:44 PM
    Aurinia Presents Additional Data from Phase IIB AURA-LV Study, Demonstrating Stable Renal Function and Blood ... - Business Wire (press release)Aurinia Presents Additional Data from Phase IIB AURA-LV Study, Demonstrating Stable Renal Function and Blood ... - Business Wire (press release)
    www.businesswire.com - June 7 at 7:41 AM
    Aurinia Reports First Quarter 2017 Financial Results, Announces Initiation of Phase III Aurora Clinical Trial, and ... - Business Wire (press release)Aurinia Reports First Quarter 2017 Financial Results, Announces Initiation of Phase III Aurora Clinical Trial, and ... - Business Wire (press release)
    www.businesswire.com - May 16 at 3:48 PM
    BRIEF-George Milne joins Aurinia’s board of directorsBRIEF-George Milne joins Aurinia’s board of directors
    www.reuters.com - May 11 at 9:10 PM
    Pharma Industry Veteran Dr. George Milne Joins Aurinias Board of Directors - Business Wire (press release)Pharma Industry Veteran Dr. George Milne Joins Aurinia's Board of Directors - Business Wire (press release)
    www.businesswire.com - May 9 at 3:45 PM
    Aurinia Closes US$173.1 Million Public Offering of Common Shares ... - Business Wire (press release)Aurinia Closes US$173.1 Million Public Offering of Common Shares ... - Business Wire (press release)
    www.businesswire.com - March 21 at 4:06 PM
    Aurinia Announces Public Offering of Common Shares - Business Wire (press release)Aurinia Announces Public Offering of Common Shares - Business Wire (press release)
    www.businesswire.com - March 14 at 6:43 AM
    EXFO, Shopify at 52-Week Highs - Baystreet.caEXFO, Shopify at 52-Week Highs - Baystreet.ca
    www.baystreet.ca - March 10 at 4:29 PM
    Aurinia Out with Annual Numbers, Hits 52-week High - Baystreet.caAurinia Out with Annual Numbers, Hits 52-week High - Baystreet.ca
    www.baystreet.ca - March 10 at 4:29 PM
    Company Spotlight: Aurinia PharmaCompany Spotlight: Aurinia Pharma
    www.rttnews.com - March 3 at 2:00 AM
    Aurinia Announces Voclosporin Meets 48-Week Remission Endpoints, Achieving Highest Complete Remission Rate of Any Global Lupus Nephritis StudyAurinia Announces Voclosporin Meets 48-Week Remission Endpoints, Achieving Highest Complete Remission Rate of Any Global Lupus Nephritis Study
    www.businesswire.com - March 1 at 8:41 PM
    Aurinia Selects Worldwide Clinical Trials as its CRO for Phase 3 Lupus Nephritis Trial - Business Wire (press release)Aurinia Selects Worldwide Clinical Trials as its CRO for Phase 3 Lupus Nephritis Trial - Business Wire (press release)
    www.businesswire.com - January 29 at 1:47 AM
    Biotech Stock Mailbag: Trump, Aurinia, Immunomedics, CellceutixBiotech Stock Mailbag: Trump, Aurinia, Immunomedics, Cellceutix
    www.thestreet.com - January 27 at 4:52 PM
    Aurinia Closes US$28 Million Financing - Business Wire (press release)Aurinia Closes US$28 Million Financing - Business Wire (press release)
    www.businesswire.com - December 29 at 2:51 AM

    Social Media

    Financials

    Financials are not available for this stock.

    Chart

    Aurinia Pharmaceuticals (TSE AUP) Chart for Friday, November, 24, 2017
    Loading chart…

    This page was last updated on 11/24/2017 by MarketBeat.com Staff

    Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.